ASX:BOTBotanix Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.04 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.04Now: A$0.04▼A$0.0450-Day RangeA$0.02MA: A$0.05▼A$0.0952-Week RangeA$0.02Now: A$0.04▼A$0.29Volume1.63 million shsAverage Volume4.45 million shsMarket Capitalization$40.85 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The company offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. Botanix Pharmaceuticals Limited is based in Perth, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Botanix Pharmaceuticals. Previous Next 2.7 Community Rank Outperform VotesBotanix Pharmaceuticals has received 62 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBotanix Pharmaceuticals has received 53 “underperform” votes. (Add your “underperform” vote.)Community SentimentBotanix Pharmaceuticals has received 53.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Botanix Pharmaceuticals and other stocks. Vote “Outperform” if you believe BOT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BOT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBotanix Pharmaceuticals does not currently pay a dividend.Dividend GrowthBotanix Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Botanix Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Botanix Pharmaceuticals is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Botanix Pharmaceuticals is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBotanix Pharmaceuticals has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:BOT Previous Symbol CUSIPN/A CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580Debt Debt-to-Equity Ratio1.33 Current Ratio17.18 Quick Ratio17.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.58 million Price / Sales5.39 Cash FlowA$0.03 per share Price / Cash Flow1.50 Book ValueA$0.03 per share Price / Book1.24Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees10 Outstanding Shares972,697,984Market Cap$40.85 million Next Earnings DateN/A OptionableNot Optionable Receive BOT News and Ratings via Email Sign-up to receive the latest news and ratings for BOT and its competitors with MarketBeat's FREE daily newsletter. Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions How has Botanix Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Botanix Pharmaceuticals' stock was trading at A$0.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BOT shares have decreased by 45.5% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus. How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Ltd (ASX:BOT) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($0.01) EPS for the quarter. View Botanix Pharmaceuticals' earnings history. Has Botanix Pharmaceuticals been receiving favorable news coverage? Headlines about BOT stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Botanix Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBotanix Pharmaceuticals. Who are some of Botanix Pharmaceuticals' key competitors? Some companies that are related to Botanix Pharmaceuticals include Horizon Discovery Group (HZD), OncoCyte (OCX), Tiziana Life Sciences (TILS), Orgenesis (ORGS), Oncolytics Biotech (ONC), Monash IVF Group (MVF), Burcon NutraScience (BU), BioTime (BTX), Lineage Cell Therapeutics (LCTX), Matinas BioPharma (MTNB), Imugene (IMU), Verseon (VSN), Lineage Cell Therapeutics (LCTX), MediGene (MDG1) and Arix Bioscience (ARIX). View all competitors. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Botanix Pharmaceuticals investors own include AgraFlora Organics International (AGFAF), Byron Energy (BYE), Harmony Gold Mining (HMY), Syrah Resources (SYR), Nike (NKE), Michael Hill International (MHJ), Lynas (LYC), Cobalt 27 Capital (KBLT), Eclipx Group (ECX) and BOD Australia (BDA). Who are Botanix Pharmaceuticals' key executives? Botanix Pharmaceuticals' management team includes the following people: Mr. Matthew Callahan, Founder & Exec. Director (Age 46)Dr. Michael Thurn Ph.D., COO & Exec. DirectorDr. Henry William Bosch, Chief Scientific Officer & Exec. DirectorDr. Stephane Levy, Chief Medical OfficerMr. Simon Robertson B.Bus, M Appl. Fin, CA, Company Sec. What is Botanix Pharmaceuticals' stock symbol? Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT." What is Botanix Pharmaceuticals' stock price today? One share of BOT stock can currently be purchased for approximately A$0.04. How big of a company is Botanix Pharmaceuticals? Botanix Pharmaceuticals has a market capitalization of $40.85 million and generates $7.58 million in revenue each year. Botanix Pharmaceuticals employs 10 workers across the globe. What is Botanix Pharmaceuticals' official website? The official website for Botanix Pharmaceuticals is www.botanixpharma.com. How can I contact Botanix Pharmaceuticals? Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580. This page was last updated on 5/26/2020 by MarketBeat.com Staff
